Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
Leo Miller

Accenture: Undervalued GenAI Leader or Snake Eating its Own Tail?

For international consulting company Accenture (NYSE: ACN), 2025 has been a rough year. Shares have provided a total return of approximately -33% as of the September 25 close. This has put the stock at a historically low valuation multiple. In fact, Accenture’s forward price-to-earnings (P/E) ratio of 17x is the lowest it has been in three years. This suggests a strong opportunity for the stock to recover, especially with its GenAI business booming.

However, given market sentiment and the company’s latest earnings, is Accenture truly a value play, or a train to nowhere for now?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.